InterLink AI

InterLink AI provides AI-based prescription error monitoring solutions tailored for pharmacies and hospitals. The platform focuses on automating medicine error detection and drug dispensation, offering service-centric visibility and actionable insights to healthcare providers. With 24/7 availability, it ensures continuous support for crisis care scenarios.

Founded in 2009 and headquartered in Omaha, InterLink AI serves institutions needing reliable, real-time error prevention in medication management. The platform is designed to integrate smoothly with existing healthcare systems, targeting mid-sized to large hospitals and pharmacy chains seeking to reduce human error in prescriptions. Its AI-driven approach aims to complement clinical workflows rather than replace them entirely, positioning it as a decision-support tool for healthcare professionals.

The company has raised $11M in funding and employs 17 people as of 2026, reflecting its niche but growing presence in the healthcare AI space. InterLink AI's core functionality centers on automated prescription auditing and anomaly detection. The system scans medication orders against patient histories, drug interactions, and dosage guidelines, flagging potential errors before dispensation.

It processes data from electronic health records (EHRs) and pharmacy management systems, providing real-time alerts to clinicians. The platform's 4.3/5 rating from 202 user reviews highlights its operational reliability in live healthcare environments. Key technical capabilities include batch processing of up to 10,000 prescriptions per hour and integration with major EHR platforms like Epic and Cerner.

The AI models are trained on proprietary datasets of prescription errors, enabling detection of both common mistakes and rare edge cases that human reviewers might miss. This technical infrastructure supports the platform's claim of reducing medication errors by up to 38% in pilot implementations. In the competitive landscape of healthcare AI, InterLink AI faces direct competition from Synapse Medicine, Zydus Verify, and Lumio Medical.

Unlike general-purpose AIOps platforms like PagerDuty or Splunk ITSI, InterLink specializes exclusively in pharmaceutical error prevention. Its $25,000 per-user annual pricing positions it as a premium solution compared to some competitors, though user reviews note better evaluation and contracting processes. The company differentiates through healthcare-specific features like crisis care protocols and pharmacy workflow integration, rather than offering broad IT monitoring capabilities.

Compared to Synapse Medicine's European focus, InterLink has stronger penetration in U.S. hospital systems, while Zydus Verify competes more aggressively in the Indian market. While InterLink AI delivers measurable error reduction, its implementation requires careful consideration of trade-offs. The platform's AI algorithms may flag false positives, requiring pharmacist review and potentially slowing some workflows.

Some users express concerns about over-reliance on automated systems potentially diminishing critical thinking skills among junior pharmacy staff. Data privacy remains a consideration, as the system requires full access to patient medication histories. Unlike human reviewers, the AI currently lacks nuanced understanding of exceptional clinical circumstances that may warrant off-protocol prescriptions. These limitations necessitate maintaining human oversight even with the platform's 24/7 availability and high detection accuracy for common error types.

$25,000 per user annually, with no publicly disclosed tiered pricing or volume discounts.